Forbes: "TrialReach And The Democratization Of Clinical Trials"

Delays in clinical trial enrollment slow down research progress. Forbes covered TrialReach's innovative approach to bringing patients and researchers together:

"This is why the platform that TrialReach announced recently in Boston at Disruptive Innovations is, actually much more than a disruptive intrusion, but a constructive change in clinical trials. TrialReach is bridging the gap between the patients and the researchers who are developing new medical treatments. The platform lets any-sized medical research team convert their protocols into simple, interactive patient-friendly pages and forms and makes it easy for millions of patients to find these trials through sites such as MedPage Today. The result is a much more effective collaboration. And in the final analysis, offers the potential for superior patient outcomes and trial results."

Read more at Forbes.